SAGE Therapeutics Inc (NASDAQ:SAGE) Director Steven M. Paul sold 3,775 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $161.05, for a total value of $607,963.75. Following the transaction, the director now owns 272,777 shares in the company, valued at $43,930,735.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Shares of SAGE Therapeutics stock traded down $3.64 during trading on Wednesday, reaching $152.46. The company’s stock had a trading volume of 1,093,680 shares, compared to its average volume of 673,082. The firm has a market capitalization of $7.35 billion, a PE ratio of -18.87 and a beta of 2.92. SAGE Therapeutics Inc has a one year low of $79.88 and a one year high of $188.82.
SAGE Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Tuesday, February 19th. The biopharmaceutical company reported ($3.38) EPS for the quarter, missing analysts’ consensus estimates of ($2.89) by ($0.49). The firm had revenue of $0.27 million during the quarter. During the same period last year, the firm earned ($1.75) EPS. On average, analysts predict that SAGE Therapeutics Inc will post -12.51 earnings per share for the current year.
Several equities analysts have weighed in on the company. Guggenheim assumed coverage on SAGE Therapeutics in a report on Friday, February 22nd. They set a “buy” rating and a $205.00 target price on the stock. BidaskClub upgraded SAGE Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, February 5th. LADENBURG THALM/SH SH set a $210.00 target price on SAGE Therapeutics and gave the company a “buy” rating in a report on Tuesday, December 11th. Oppenheimer set a $170.00 target price on SAGE Therapeutics and gave the company a “buy” rating in a report on Tuesday, November 20th. Finally, Wolfe Research assumed coverage on SAGE Therapeutics in a report on Friday, December 14th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $201.45.
Several institutional investors have recently bought and sold shares of the company. Virtus ETF Advisers LLC increased its stake in shares of SAGE Therapeutics by 2.7% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,948 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 77 shares during the period. Daiwa Securities Group Inc. increased its stake in shares of SAGE Therapeutics by 34.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 310 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 80 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of SAGE Therapeutics by 2.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,676 shares of the biopharmaceutical company’s stock worth $831,000 after purchasing an additional 239 shares during the period. Principal Financial Group Inc. increased its stake in shares of SAGE Therapeutics by 1.1% in the fourth quarter. Principal Financial Group Inc. now owns 23,202 shares of the biopharmaceutical company’s stock worth $2,222,000 after purchasing an additional 243 shares during the period. Finally, Benjamin F. Edwards & Company Inc. bought a new position in shares of SAGE Therapeutics in the fourth quarter worth about $29,000.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2019/03/20/sage-therapeutics-inc-sage-director-steven-m-paul-sells-3775-shares.html.
SAGE Therapeutics Company Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).
Featured Article: Technical Analysis
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.